Dogwood Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a nine-month net loss of $21,399,165 and cash of $4,948,266.

Key Highlights

  • Net loss (nine months): The company reported a net loss of $21,399,165 for the nine months ended September 30, 2026, compared to $30,476,921 for the same period in 2025.
  • Quarterly net loss: Net loss for the three months ended September 30, 2026 was $4,882,942, versus $15,744,616 in the prior-year quarter.
  • Cash position: Cash and cash equivalents stood at $4,948,266 as of September 30, 2026, down from $6,524,744 at December 31, 2025.
  • IPR&D impairment: The company recorded an in-process research and development impairment charge of $9,190,897 in the nine months ended September 30, 2026, with no comparable charge in the prior-year period.
  • Licensing revenue: Total revenue of $100,000 was recorded for both the three and nine months ended September 30, 2026, entirely from licensing, compared to zero revenue in the prior-year periods.
  • Shares outstanding: As of November 3, 2026, there were 38,227,913 shares of common stock outstanding.
  • Total assets: Total assets were $75,608,219 at September 30, 2026, down from $90,171,237 at December 31, 2025.

Dogwood Therapeutics Reports Q3 2026 Financial Results, Including IPR&D Impairment and First Licensing Revenue

According to the filing, Dogwood Therapeutics (NASDAQ:DWTX) reported a net loss of $4,882,942 for the three months ended September 30, 2026, compared to a net loss of $15,744,616 for the same quarter in 2025. Research and development expenses declined significantly, to $3,352,977 in Q3 2026 from $14,521,342 in Q3 2025. General and administrative expenses were $1,576,219 for the quarter, up from $1,287,783 in the prior-year period.

For the nine months ended September 30, 2026, the company disclosed total operating expenses of $24,069,087, which included the $9,190,897 IPR&D impairment charge recorded in the period. The company reported gross profit of $11,896 for both the three- and nine-month periods, reflecting $100,000 in licensing revenue offset by $88,104 in CVR expense classified as cost of goods sold. No revenue was recorded in the comparable 2025 periods, according to the filing.

The balance sheet as of September 30, 2026 showed total liabilities of $11,475,000 and total stockholders' equity of $64,133,219. The accumulated deficit grew to $129,475,481 from $108,076,316 at December 31, 2025. Intangible assets were reported at $57,436,292, down from $68,985,026 at year-end 2025. The company disclosed a deferred tax liability of $9,213,783 and recorded a deferred income tax benefit of $2,480,340 for the nine-month period. Net loss per common share, basic and diluted, was $(0.63) for the nine months ended September 30, 2026, based on a weighted average of 33,936,760 shares outstanding.

What Was Disclosed

Dogwood Therapeutics filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $21,399,165, an IPR&D impairment of $9,190,897, first-ever licensing revenue of $100,000, and cash of $4,948,266 as of the period end.